BioMedNewsBreaks

TuesdayNov 10, 2026 10:10 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Publishes Phase 1a Glioblastoma Data, Advances LP-184 Combination Therapy Toward Phase 1b/2a Trial

Lantern Pharma (NASDAQ: LTRN) and its wholly owned subsidiary, Starlight Therapeutics, announced the publication of Phase 1a clinical data for LP-184 (zirdafulven), also being developed as STAR-001, in patients with recurrent glioblastoma ("GBM"). Published in the October 2026 issue of Cancer Research Communications, the study evaluated 16 patients and found LP-184 was generally well tolerated, establishing a recommended expansion dose of 0.39 mg/kg. No objective radiographic responses were observed, although one patient remained clinically and radiographically stable for more than 22 months after enrollment. The findings also identified limited drug exposure in brain tumors, supporting further evaluation of LP-184 in…

Continue Reading

MondayNov 09, 2026 12:19 pm

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Signs Four-Year Exclusive Distribution Agreement for GelrinC (R) in Israel

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, announced a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. for the commercialization of GelrinC (R), its proprietary implant for repairing damaged knee cartilage, in Israel. GelrinC has received regulatory approval from Israel's Ministry of Health for the same indication approved in Europe and being pursued in the United States. Under the agreement, AMI will leverage its established relationships with orthopedic surgeons, hospitals and clinics to support the product's commercial introduction. The agreement includes minimum purchase requirements, with Regentis expecting initial revenue contributions beginning in…

Continue Reading

FridayNov 06, 2026 10:09 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Files Supplement to Shareholder Meeting Materials Clarifying Share Consolidation Terms

Quantum BioPharma (NASDAQ: QNTM) announced that it has filed a supplement to its Sept. 28, 2026, management information circular ahead of its annual general and special meeting of shareholders scheduled for Nov. 10, 2026. The supplement corrects and restates the proposed special resolution authorizing a consolidation of the company's Class A multiple voting shares and Class B subordinate voting shares. Under the clarified terms, fractional shares equal to or less than one-half will be rounded down to the nearest whole share, while fractions greater than one-half will be rounded up. The company also clarified that it will implement measures to…

Continue Reading

ThursdayNov 05, 2026 2:43 pm

BioMedNewsBreaks – Earth Science Tech Inc. (ETST) Builds Long-Term Value Through Strategic Integration

Earth Science Tech (OTCQB: ETST), a diversified holding company operating across healthcare, pharmacy, technology, telemedicine, real estate, and consumer products, is leveraging synergies among its subsidiaries to support long-term growth and generate dependable revenue. Its real estate and asset management subsidiary, Avenvi LLC, contributes to this strategy through its diversified real estate portfolio, property development expertise, and financing solutions for property purchasers. In addition to managing investments and overseeing ETST’s share repurchase program, Avenvi provides essential physical infrastructure for the company’s expanding pharmacy operations, including housing the standalone Mister Meds compounding pharmacy in Texas. Through its real estate capabilities, disciplined…

Continue Reading

ThursdayNov 05, 2026 2:06 pm

BioMedNewsBreaks – Why Adaptogenics Health Corp. (CSE: ADPT) Is ‘One to Watch’

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT) was featured in a recent article that discussed its efforts to build a healthcare company focused on opportunities across the rapidly evolving peptide sector, combining proprietary therapeutic development, pharmaceutical-quality supply infrastructure and innovative drug delivery technologies. “As demand for solutions addressing metabolic health, muscle preservation, recovery and healthy ageing continues to grow, Adaptogenics is positioning itself to address significant healthcare challenges while pursuing opportunities in the expanding market for high-quality peptide development and supply,” the article reads. “The company’s strategy combines experienced pharmaceutical leadership, scientific…

Continue Reading

FridayOct 30, 2026 1:59 pm

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands NAMs Strategy to Advance BiTAC(R) Therapies

VERAXA Biotech (NASDAQ: VRXA) is expanding its use of human-relevant preclinical testing methods across its antibody-based cancer drug development programs, aiming to improve the clinical relevance of research findings while reducing animal testing. The company is implementing New Approach Methodologies (“NAMs”), including three-dimensional tumor spheroid models and patient-derived tumor models, in support of its BiTAC(R) T-cell engagers, antibody-drug conjugates and bispecific antibody-drug conjugates. VERAXA reported that its lead BiTAC T-cell engager demonstrated selective, potent T-cell-mediated tumor-cell killing across 10 patient-derived non-small cell lung cancer models, while relevant controls showed minimal activity. The ex vivo study required approximately 10 mice, compared…

Continue Reading

FridayOct 30, 2026 1:00 pm

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Taps Thermo Fisher’s Clinical Research Business for Lucid-MS Trial

Quantum BioPharma (NASDAQ: QNTM) has signed a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical research business to support the Phase 2 clinical trial of Lucid-MS, its investigational drug candidate for progressive multiple sclerosis (“MS”). Following U.S. Food and Drug Administration clearance of its Investigational New Drug application in August 2026, the agreement moves the program toward clinical implementation with a contract research organization experienced in central nervous system and MS studies. Unlike many existing MS treatments that primarily target the immune system, Lucid-MS is designed to protect myelin, the protective coating around nerve fibers, by inhibiting PAD2, an enzyme…

Continue Reading

FridayOct 30, 2026 10:22 am

BioMedNewsBreaks – Adaptogenics Health Corp. (CSE: ADPT) Gains Industry Relevance as FDA Eases Restrictions on Pharmacy-Compounded Peptides, NBC News Reports

This article has been disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT) is drawing attention amid changes to the regulatory environment for peptide-based treatments, as federal health officials move to allow compounding pharmacies to immediately offer six previously restricted peptides without waiting for formal rulemaking. According to an Oct. 28 NBC News report by Berkeley Lovelace Jr ., the Department of Health and Human Services is exercising “enforcement discretion,” temporarily suspending legal action against qualifying pharmacies that compound BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. The Food and Drug Administration (“FDA”) is requiring…

Continue Reading

FridayOct 30, 2026 10:19 am

BioMedNewsBreaks – Adaptogenics Health Corp. (CSE: ADPT) Sees Regulatory Landscape Shift as Federal Policy Permits Compounding of Six Peptides, Reuters Reports

This article has been disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT) operates in a peptide sector undergoing a significant regulatory shift following the publication of a new federal policy permitting licensed pharmacies and physicians to compound six previously restricted peptides under specified conditions. According to an Oct. 28 Reuters report by Sneha S K, with additional reporting by Kamal Choudhury and Siddhi Mahatole , the policy, published in the Federal Register, allows compounding of BPC-157, TB-500, epitalon, KPV, MOTS-c and Semax without Food and Drug Administration (“FDA”) enforcement action, provided compounders meet…

Continue Reading

ThursdayOct 29, 2026 2:21 pm

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Highlights Potential of GelrinC Cartilage Repair Technology

Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article that discussed the company’s efforts to advance its regenerative cartilage repair technology, GelrinC, as orthopedic medicine increasingly emphasizes durable, long-term treatment outcomes. The company’s lead product is a cell-free, off-the-shelf degradable hydrogel implant designed to support the regeneration of knee cartilage, gradually resorbing over approximately six to nine months as new tissue fills the treated area. Regentis reports that its Pilot/Phase II study showed 100% greater pain improvement compared with traditional microfracture treatment, while 24-month follow-up results showed a mean MOCART score of 88.8 out of 100, an MRI-based measure…

Continue Reading